Metabolic improvements in intrahepatic porto-systemic venous shunt presenting various metabolic abnormalities by 4-phenylacetate

Hironori Nagasaka, Takashi Miida, Tohru Yorifuji, Ken Ichi Hirano, Ayano Inui, Tomoo Fujisawa, Hirokazu Tsukahara, Hisamitsu Hayashi, Yukihiro Inomata

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Intrahepatic congenital portosystemic venous shunt (CPSVS) presents hyperammonemia, cholestasis, hypergalactosemia and imbalanced vasomediators. Especially, fluctuating plasma ammonia often causing neurological signs and symptoms is a serious problem in the daily life. 4-Phenylacetate (4-PA) has effects to eliminate blood ammonia, bile acids and bilirubin. 4-PA might be expected to improve the metabolic abnormalities in intrahepatic CPSVS. Methods: Three intrahepatic CPSVS children often receiving 4-PA from early life were enrolled. We analyzed biological and clinical changes by intravenous administration of 4-PA. Results: 4-PA improved hyperammonemia enough to subside the clinical presentations: headache, cognition dysfunction and attention deficit. Concurrently, this drug decreased serum total bilirubin and total bile acid levels. In their neonatal ages, 4-PA also decreased galactose and galactose-1-phosphate levels. In their preschool or school ages, 4-PA increased nitric oxide (NO) prompting vasodilation, but not changed amino acids controlling NO production and endothelin-1 prompting vasoconstriction. Plasma ammonia level returned to the pre-administration level within one day of the discontinuation, and serum total bilirubin and total bile acid levels were maintained to be reduced a few days after the discontinuation. Conclusion: 4-PA improves galactosemia and imbalanced vasomediators, together with liver functions, in CPSVS, although such effects retract after the discontinuation.

Original languageEnglish
Pages (from-to)52-56
Number of pages5
JournalClinica Chimica Acta
Volume419
DOIs
Publication statusPublished - Apr 8 2013

Fingerprint

Bile Acids and Salts
Bilirubin
Ammonia
Hyperammonemia
Nitric Oxide
Galactosemias
Plasmas
phenylacetic acid
Cholestasis
Endothelin-1
Vasoconstriction
Serum
Galactose
Vasodilation
Intravenous Administration
Liver
Cognition
Signs and Symptoms
Headache
Blood

Keywords

  • 4-Phenylacetate
  • Cholestasis
  • Galactosemia
  • Hyperammonemia
  • Nitric oxide
  • Portosystemic venous shunt

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Metabolic improvements in intrahepatic porto-systemic venous shunt presenting various metabolic abnormalities by 4-phenylacetate. / Nagasaka, Hironori; Miida, Takashi; Yorifuji, Tohru; Hirano, Ken Ichi; Inui, Ayano; Fujisawa, Tomoo; Tsukahara, Hirokazu; Hayashi, Hisamitsu; Inomata, Yukihiro.

In: Clinica Chimica Acta, Vol. 419, 08.04.2013, p. 52-56.

Research output: Contribution to journalArticle

Nagasaka, Hironori ; Miida, Takashi ; Yorifuji, Tohru ; Hirano, Ken Ichi ; Inui, Ayano ; Fujisawa, Tomoo ; Tsukahara, Hirokazu ; Hayashi, Hisamitsu ; Inomata, Yukihiro. / Metabolic improvements in intrahepatic porto-systemic venous shunt presenting various metabolic abnormalities by 4-phenylacetate. In: Clinica Chimica Acta. 2013 ; Vol. 419. pp. 52-56.
@article{64ec4fcd65154913860df5e9334d83e3,
title = "Metabolic improvements in intrahepatic porto-systemic venous shunt presenting various metabolic abnormalities by 4-phenylacetate",
abstract = "Background: Intrahepatic congenital portosystemic venous shunt (CPSVS) presents hyperammonemia, cholestasis, hypergalactosemia and imbalanced vasomediators. Especially, fluctuating plasma ammonia often causing neurological signs and symptoms is a serious problem in the daily life. 4-Phenylacetate (4-PA) has effects to eliminate blood ammonia, bile acids and bilirubin. 4-PA might be expected to improve the metabolic abnormalities in intrahepatic CPSVS. Methods: Three intrahepatic CPSVS children often receiving 4-PA from early life were enrolled. We analyzed biological and clinical changes by intravenous administration of 4-PA. Results: 4-PA improved hyperammonemia enough to subside the clinical presentations: headache, cognition dysfunction and attention deficit. Concurrently, this drug decreased serum total bilirubin and total bile acid levels. In their neonatal ages, 4-PA also decreased galactose and galactose-1-phosphate levels. In their preschool or school ages, 4-PA increased nitric oxide (NO) prompting vasodilation, but not changed amino acids controlling NO production and endothelin-1 prompting vasoconstriction. Plasma ammonia level returned to the pre-administration level within one day of the discontinuation, and serum total bilirubin and total bile acid levels were maintained to be reduced a few days after the discontinuation. Conclusion: 4-PA improves galactosemia and imbalanced vasomediators, together with liver functions, in CPSVS, although such effects retract after the discontinuation.",
keywords = "4-Phenylacetate, Cholestasis, Galactosemia, Hyperammonemia, Nitric oxide, Portosystemic venous shunt",
author = "Hironori Nagasaka and Takashi Miida and Tohru Yorifuji and Hirano, {Ken Ichi} and Ayano Inui and Tomoo Fujisawa and Hirokazu Tsukahara and Hisamitsu Hayashi and Yukihiro Inomata",
year = "2013",
month = "4",
day = "8",
doi = "10.1016/j.cca.2013.01.016",
language = "English",
volume = "419",
pages = "52--56",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Metabolic improvements in intrahepatic porto-systemic venous shunt presenting various metabolic abnormalities by 4-phenylacetate

AU - Nagasaka, Hironori

AU - Miida, Takashi

AU - Yorifuji, Tohru

AU - Hirano, Ken Ichi

AU - Inui, Ayano

AU - Fujisawa, Tomoo

AU - Tsukahara, Hirokazu

AU - Hayashi, Hisamitsu

AU - Inomata, Yukihiro

PY - 2013/4/8

Y1 - 2013/4/8

N2 - Background: Intrahepatic congenital portosystemic venous shunt (CPSVS) presents hyperammonemia, cholestasis, hypergalactosemia and imbalanced vasomediators. Especially, fluctuating plasma ammonia often causing neurological signs and symptoms is a serious problem in the daily life. 4-Phenylacetate (4-PA) has effects to eliminate blood ammonia, bile acids and bilirubin. 4-PA might be expected to improve the metabolic abnormalities in intrahepatic CPSVS. Methods: Three intrahepatic CPSVS children often receiving 4-PA from early life were enrolled. We analyzed biological and clinical changes by intravenous administration of 4-PA. Results: 4-PA improved hyperammonemia enough to subside the clinical presentations: headache, cognition dysfunction and attention deficit. Concurrently, this drug decreased serum total bilirubin and total bile acid levels. In their neonatal ages, 4-PA also decreased galactose and galactose-1-phosphate levels. In their preschool or school ages, 4-PA increased nitric oxide (NO) prompting vasodilation, but not changed amino acids controlling NO production and endothelin-1 prompting vasoconstriction. Plasma ammonia level returned to the pre-administration level within one day of the discontinuation, and serum total bilirubin and total bile acid levels were maintained to be reduced a few days after the discontinuation. Conclusion: 4-PA improves galactosemia and imbalanced vasomediators, together with liver functions, in CPSVS, although such effects retract after the discontinuation.

AB - Background: Intrahepatic congenital portosystemic venous shunt (CPSVS) presents hyperammonemia, cholestasis, hypergalactosemia and imbalanced vasomediators. Especially, fluctuating plasma ammonia often causing neurological signs and symptoms is a serious problem in the daily life. 4-Phenylacetate (4-PA) has effects to eliminate blood ammonia, bile acids and bilirubin. 4-PA might be expected to improve the metabolic abnormalities in intrahepatic CPSVS. Methods: Three intrahepatic CPSVS children often receiving 4-PA from early life were enrolled. We analyzed biological and clinical changes by intravenous administration of 4-PA. Results: 4-PA improved hyperammonemia enough to subside the clinical presentations: headache, cognition dysfunction and attention deficit. Concurrently, this drug decreased serum total bilirubin and total bile acid levels. In their neonatal ages, 4-PA also decreased galactose and galactose-1-phosphate levels. In their preschool or school ages, 4-PA increased nitric oxide (NO) prompting vasodilation, but not changed amino acids controlling NO production and endothelin-1 prompting vasoconstriction. Plasma ammonia level returned to the pre-administration level within one day of the discontinuation, and serum total bilirubin and total bile acid levels were maintained to be reduced a few days after the discontinuation. Conclusion: 4-PA improves galactosemia and imbalanced vasomediators, together with liver functions, in CPSVS, although such effects retract after the discontinuation.

KW - 4-Phenylacetate

KW - Cholestasis

KW - Galactosemia

KW - Hyperammonemia

KW - Nitric oxide

KW - Portosystemic venous shunt

UR - http://www.scopus.com/inward/record.url?scp=84874374818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874374818&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2013.01.016

DO - 10.1016/j.cca.2013.01.016

M3 - Article

C2 - 23399721

AN - SCOPUS:84874374818

VL - 419

SP - 52

EP - 56

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -